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Isolation of specific cell types, including pluripotent
stem cell (PSC)-derived populations, is frequently
accomplished using cell surface antigens ex-
pressed by the cells of interest. However, specific
antigens for many cell types have not been iden-
tified, making their isolation difficult. Here, we
describe an efficient method for purifying cells
based on endogenous miRNA activity. We designed
synthetic mRNAs encoding a fluorescent protein
tagged with sequences targeted by miRNAs ex-
pressed by the cells of interest. These miRNA
switches control their translation levels by sensing
miRNA activities. Several miRNA switches (miR-1-,
miR-208a-, and miR-499a-5p-switches) efficiently
purified cardiomyocytes differentiated from human
PSCs, and switches encoding the apoptosis
inducer Bim enriched for cardiomyocytes without
cell sorting. This approach is generally applicable,
as miR-126-, miR-122-5p-, and miR-375-switches
purified endothelial cells, hepatocytes, and insulin-
producing cells differentiated from hPSCs, respec-
tively. Thus, miRNA switches can purify cell
populations for which other isolation strategies are
unavailable.
INTRODUCTION
Cardiovascular disease is the most common cause of death
worldwide. Many therapeutic strategies to treat cardiovascular
disease are being investigated, including human pluripotent
stem cells (hPSCs), such as embryonic stem cells (hESCs)
and induced pluripotent stem cells (hiPSCs), which can
produce a variety of cell types and which are a potential cell
source for transplantation therapy, drug efficiency evaluation,and toxicology testing (Garbern and Lee, 2013; Takahashi
et al., 2007; Yu et al., 2007). In particular, the transplantation
of cardiomyocytes derived from hPSCs is a promising strategy
for reconstructing damaged myocardium.
Although several studies on the differentiation of hPSCs
into cardiomyocytes have been reported (Kawamura et al.,
2013; Laflamme et al., 2007; Li et al., 2011; White et al.,
2013; Yang et al., 2008), the resulting differentiated cells
are often a mixture of heterogeneous populations. Therefore,
the purification of distinct target cells, such as cardiomyocytes,
is an important step for safe and controllable cell therapy.
However, many types of cells, including cardiomyocytes,
have no specific cell surface markers that facilitate their iden-
tification, thus hindering the clinical applications of hPSC-
derived cells.
To overcome this problem, several methods have been
devised for purifying hPSC-derived cardiomyocytes. Examples
include a Percoll density gradient procedure (Laflamme et al.,
2007; Xu et al., 2002); genetic manipulation of hPSCs using
cardiac promoters (Anderson et al., 2007; Bizy et al., 2013; El-
liott et al., 2011); cell sorting using mitochondrial dyes (Hattori
et al., 2010), molecular beacons that target cardiomyocyte-
specific mRNA (Ban et al., 2013) or antibodies against cardiac
cell surface markers, including signal-regulatory protein alpha
(SIRPA) (Dubois et al., 2011) and vascular cell adhesion mole-
cule 1 (VCAM1) (Elliott et al., 2011; Uosaki et al., 2011); and
metabolic selection using glucose-depleted culture medium
containing lactate (Tohyama et al., 2013). Some of these
methods, such as those that require genetic modification, are
likely inappropriate for transplantation therapy. Although cell
sorting using antibodies should initially enable enrichment of
cardiomyocytes, markers such as SIRPA and VCAM1 are ex-
pressed in other cell types (Dubois et al., 2011; Osborn et al.,
1989). This potential non-specificity could cause contamination
by non-cardiomyocytes, affecting the efficacy of the transplan-
tation. Moreover, antibodies on the surface of transplanted
cells may be immunogenic and cause local inflammation or
graft failure. Therefore, we investigated an alternative purifica-
tion method that is based on detecting and distinguishingCell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc. 699
Figure 1. Measurement of miRNA Activity Using miRNA Switches
(A) Schematic representation of miRNA switch function.
(B) Scheme of target cell purification using a cell-type-specific miRNA switch.
(C) Design of a miRNA switch synthesized in vitro. The upper and lower constructs contain one miRNA target site in the 50 UTR and four sites in the 30 UTR,
respectively, as well as a fluorescent protein coding sequence. Each target site was completely complementary to the miRNA of interest. Synthesized mRNAs
contain anti-reverse cap analog (ARCA) at the 50 end and a poly(A) tail of 120 nucleotides (A120).
(D) Translational efficiency of the designed mRNAs measured in the presence of a miRNA inhibitor. Reporter mRNAs expressing EGFP and the control tagRFP
mRNAwere transfected into HeLa cells together with amiRNA inhibitor. The inhibitor was responsive tomiR-21-5p ormiR-17-5p (corresponding, red) or tomiR-1
(negative control, gray). Translational efficiencywas defined as themean intensity of EGFP divided by that of tagRFP, followed by normalization with control EGFP
mRNA. The error bars indicate the mean ± SD (n = 5).
(E) Left, analysis of endogenous miR-21-5p expression by qRT-PCR. The error bars indicate the geometric mean ± SD from two independent triplicates.
Right, translational efficiency of miR-21-5p-EGFP-switch in HeLa and 293FT cells. The fold change is shown at the top. The error bars indicate the mean ± SD
(n = 3).
(F) Dot plots of HeLa (magenta) and 293FT (cyan) cells. The cells were transfected with miR-21-5p-EGFP-switch (FL1) and control hmKO2 mRNA (FL2) and
analyzed by flow cytometry 24 hr later.microRNA (miRNA) activities in living target cells from non-
target cells.
miRNAs are small non-coding RNAs that downregulate gene
expression by translational repression or mRNA cleavage (Fig-
ure 1A). Recent progress in synthetic biology approaches (Khalil
and Collins, 2010; Ye et al., 2013; Zhang and Seelig, 2011) has
demonstrated that DNA-based genetic circuits can control
gene expression depending on miRNA activities (Leisner et al.,
2010; Rinaudo et al., 2007; Xie et al., 2011). However, DNA-
based circuits have the potential risk of genome incorpora-
tion. To avoid potential genomic damage, modified mRNAs
(modRNAs) have been used to reprogram human somatic cells
into hPSCs (Warren et al., 2010). The in vivo injection of a
modRNA into an ischemic heart also improved cardiac function
and long-term survival (Zangi et al., 2013).700 Cell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc.We hypothesized that the use of a miRNA-responsive, syn-
thetic modRNA switch (miRNA switch) could enable better
purification of desired cell types differentiated from hPSCs
in terms of efficiency, selectivity, and safety (Figures 1A
and 1B). The miRNA switches were designed such that their
translation level was dependent on the target miRNA activity.
We also found that the selective induction of apoptosis in
non-target cells triggered by the miR-Bim-switch autono-
mously purified cardiomyocytes without cell sorting, a process
that may damage cells. Furthermore, the corresponding miRNA
switches efficiently purified endothelial cells, hepatocytes
and INSULIN-producing cells differentiated from hPSCs.
Thus, this miRNA switch technology could be useful to purify
desired cell types for future therapeutic applications and
regenerative medicine.
RESULTS
Design and Evaluation of miRNA Switches in HeLa Cells
We first designed and evaluated the function of miRNA switches
in cells from the human HeLa cell line. We initially designed two
reporter mRNAs that contained a miRNA target sequence that is
completely complementary to the miRNA at either the 50 UTR or
the 30 UTR based onmiRBase 19 (Kozomara andGriffiths-Jones,
2011). The antisense sequence for a particular miRNA was pre-
sent as either a single copy or four copies in the 50 UTR or 30 UTR
of the mRNA, respectively (Figure 1C). To compare the sensitiv-
ities in detecting the activity of endogenous miRNA for these two
miRNA switch types, we designed both types to be responsive
to miR-21-5p and miR-17-5p (both of which are active in HeLa
cells) and transfected each mRNA into the cells (Figure 1D).
In the absence of an inhibitor for the particular miRNA, the trans-
lation efficiency of the reporter EGFP was lower when the anti-
sense sequence was incorporated upstream (50 UTR) of the
ORF than downstream (30 UTR) of the ORF (Figure 1D, gray
bars). The EGFP production level was readily recovered in the
presence of the corresponding inhibitor (Figure 1D, red bars).
These results indicate that transferred mRNA with a single target
site in the 50 UTR can respond to endogenous miRNAs and
repress translation more effectively. Thus, we inserted a single
miRNA target site in the 50 UTR of reporter mRNA and used
this product as a platform to design the miRNA switch.
We investigated whether the designed miRNA switch could
distinguish the HeLa cells from 293FT cells. Using EGFP-
mRNA that responds to miR-21-5p (miR-21-5p-EGFP-switch),
we compared the translational repression efficiency between
HeLa and 293FT cells. The measured translational efficiency in
HeLa cells was 17-fold lower than that in 293FT cells, indicating
higher miR-21-5p activity in HeLa cells than in 293FT cells (Fig-
ure 1E, right). We performed qRT-PCR analysis and confirmed
that the expression level of endogenous miR-21-5p in HeLa cells
was higher than that in 293FT cells (Figure 1E, left). Next, we co-
transfected both miR-21-5p-EGFP-switch and the control, i.e.,
humanized monomeric Kusabira-Orange 2 mRNA (hmKO2).
Interestingly, we observed clearly separated HeLa and 293FT
cell populations that were co-transfected with these twomRNAs
(Figure 1F). The dot plot shows specific and sharp bands of two
cell types in which one reporter fluorescent signal (EGFP or
FL1) was in direct proportion to the other (hmKO2 or FL2). This
result indicates that the ratio of the twofluorescent proteins trans-
lated from the twomRNAs is almost constant in the population of
one cell type and is determined by miRNA activity, regardless of
the amount of modRNA that each cell receives. This demon-
strates that HeLa cells can be identified and separated from
293FT cells using our synthetic miRNA switch approach.
Screening for Cardiac-Specific miRNA Candidates
We next investigated whether the designed miRNA switch could
be used to identify and purify hPSC-derived cardiomyocytes.We
screened for cardiac-specific miRNAs using a hiPSC line into
which a human MYH6 promoter driven-EGFP reporter cassette
was integrated (MYH6-EIP4) (S.F., K.M., T.T., C.O., T. Hatani,
K. Chonabayashi, M.N., I.T., A.O., M.N., T. Kimura., S.Y., and
Y.Y., unpublished data). MYH6-EIP4 hiPSCs were differentiated
into cardiomyocytes using the appropriate concentrations of Ac-tivin A and BMP4 (see Supplemental Experimental Procedures).
EGFP-positive (EGFP+) cells appeared from day 8 (Figure S1A),
and most of the sorted EGFP+ cells at day 8 and day 20 ex-
pressed the cardiac isoform of Troponin T (cTNT), a cardiomyo-
cyte-specific marker (Figure S1B).
To select for cardiomyocyte-specific miRNA candidates, we
compared the expression profiles of miRNA between EGFP+
cardiomyocytes and EGFP- non-cardiomyocytes derived from
the MYH6-EIP4 iPSC line at day 8 and day 20. We identified
differentially expressed miRNAs at day 8 (28 candidates)
and day 20 (81 candidates; fold change >4). Among them, 14
miRNAs were shared between the day 8 and day 20 differentially
expressed miRNA groups (Figures 2A–2C). Accordingly, we syn-
thesized 14 miRNA switches that included the sequence of blue
fluorescent protein (BFP) as a reporter (miR-BFP-switch). To
evaluate the function of these miR-BFP switches, we individually
transfected the switches with control EGFP mRNA into differen-
tiated cells, including hiPSC-derived cardiomyocytes (201B7 cell
line (Takahashi et al., 2007), day 19 of differentiation). Interest-
ingly, we found that BFP signals translated from three miRNA
(miR-1, miR-208a, andmiR-499a-5p) switches clearly separated
the cells into two populations within a heterogeneous starting
population (Figure 2D), whereas the signal from control BFP
mRNA did not, indicating that miR-1-, miR-208a-, and miR-
499a-5p-switches repressed BFP translation by interacting
with the corresponding miRNAs expressed in the cardiomyo-
cytes. Additionally, miR-143-3p-, miR-490-3p-, and miR-490-
5p-switches did not clearly separate the cells into two subpopu-
lations. The other eight miRNA switches did not significantly
repress BFP signals compared with control BFP mRNA. Thus,
we focused on miR-1-, miR-208a-, and miR-499a-5p-switches
as candidates for the purification of cardiomyocytes.
Purification of hPSC-Derived Cardiomyocytes
To investigate whether miRNA switches could purify hPSC-
derived cardiomyocytes, we collected separated cells with
repressed BFP signals (gated cells are enclosed by the red solid
line in Figure 2D) by cell sorting on day 20 and analyzed cTNT
expression by flow cytometric analysis (Figure S2A). Most of
the sorted cells with miR-1-, miR-208a- and miR-499a-5p-
switches were cTNT-positive cells (cTNT+; miR-1, 95.73% ±
1.44%; miR-208a, 96.17% ± 1.29%; miR-499a-5p, 95.5% ±
2.28%), whereas those cells sorted with miR-143-3p-switch
showed a lower percentage of cTNT+ cells (30.07% ± 10.57%),
similar to cells sorted with the deficient miR-490-3p-switch
(27.40% ± 9.32%) and to control cells without sorting
(24.43% ± 2.16%; Figure 3A and Figure S2A). To compare the
purification efficiencies with existing methods, we purified cardi-
omyocytes from 201B7-derived differentiated cells on day 20
using the cardiac-specific surface marker SIRPA+ LIN (CD31,
CD49a, CD90, and CD140b) (Dubois et al., 2011) or VCAM1+
(Uosaki et al., 2011) (Figures S2B and S2C). The percentages
of cTNT+ cardiomyocytes in SIRPA+ LIN and VCAM1+ cells
were 75.27% ± 13.09% and 49.33% ± 4.76%, respectively, indi-
cating that miRNA switches can purify cTNT+ cells more effi-
ciently (Figure 3A). We also compared the false negative rate of
the isolation method by sorting the unreacted cells using either
miRNA switches or antibodies (SIRPA and VCAM1) to collect a
non-targeted cell population (negative fraction). The proportionsCell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc. 701
Figure 2. Identification of Cardiac-Specific
miRNA in hiPSC-Derived Cardiomyocytes
(A) Scatter plot of MYH6-EIP4-derived EGFP+ and
EGFP cells on day 8 and day 20. The red dots
are candidate miRNAs significantly expressed
in EGFP+ cells compared with EGFP cells (fold
change >4).
(B) Venn diagram of day 20 and day 8 candidates.
(C) List of cardiac-specific miRNA candidates.
(D) Flow cytometric analysis of candidate miRNA
switches using 201B7-derived differentiated cells.
Solid and dashed red lines represent repressed
and non-repressed BFP signals, respectively.
See also Figure S1.of cTNT+ cardiomyocytes in the negative fraction were 7.95% ±
2.24% (miR-1), 8.85% ± 5.10% (miR-208), 17.96% ± 10.99%
(miR-499a-5p), 11.40% ± 6.32% (SIRPA+ LIN), and 21.25% ±
6.76% (VCAM1+). In the case of miRNA switches, most of702 Cell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc.cTNT+ cells in the negative fraction
showed no EGFP expression, indicating
that these cTNT+ cells were mRNA non-
transfected cells (Figure S2D). In addi-
tion, hierarchical clustering of the cells
sorted by these purification methods
demonstrated that the gene expression
profiles of miR-208a-switch-sorted cells
are similar to MYH-EIP4 EGFP+- or
the antibody-sorted cells (Figure S2E).
These results verified that the miRNA
switches isolated cTNT+ cardiomyocytes
with high accuracy and efficiency.
To investigate whether the three
miRNA switches could detect and
purify cardiomyocytes derived from other
hPSC lines, we analyzed differentiated
cells from three different hiPSC lines
(409B2, 606A1, and 947A2) and from
one hESC line (KhES1). We analyzed the
percentages of cTNT+ cells after sorting
the differentiated cells from each of the
four hPSC lines using the following three
purification approaches: repressed and
unrepressed (negative fraction) BFP sig-
nals in the miRNA switch-transfected
cells, the SIRPA+ LIN cells, and the
VCAM1+ cells. All three miRNA switches
showed high purification efficiencies
(more than 95%) for all four hPSC lines
(Figure 3B and Table S1), whereas the
proportion of cTNT+ cells sorted by
SIRPA+ LIN or VCAM1+ cells ranged be-
tween 60% and 85%. Immunocytochem-
istry of the cardiomyocytes purified using
miR-1-, miR-208a-, and miR-499a-5p-
switches confirmed that most of the
sorted cells were positive for cTNT (Fig-
ure 3C, top), while the cells in each nega-
tive fraction contained a small number ofcTNT+ cells (Figure 3C, bottom), most of which were considered
non-transfected cells. These results indicate that the miRNA
switches have high efficiency and robustness for the purification
of cardiomyocytes.
To further determine whether miR-1-, miR-208a-, and miR-
499a-5p-switches isolate cardiomyocytes during the early
phase of cardiomyocyte differentiation, we transfected the
miRNA switches into differentiated cells on day 8 instead of
day 20, and the cTNT analysis was performed 1 day later
(day 9). The miR-208a-switch efficiently purified cTNT+ cardio-
myocytes (>95%), whereas miR-1-switch had poor separation
and sorting purity (Figure 3D and Figure S3A). miR-499a-5p-
switch did not react to day 8 differentiated cells (Figure S3A).
When sorting SIRPA+ LIN cells at day 9, cTNT+ cardiomyocytes
were modestly enriched in a manner similar to miR-1-switch
sorting, and VCAM1+ cells were not detected in day 9 differenti-
ated cells (Figure 3D and Figure S3A). Taken together, miR-
208a-switch had the best performance, isolating even primitive
cTNT+ cardiomyocytes with high accuracy.
Functional Evaluation of Cardiomyocytes Purified by
miR-1-Switch
As a representative miRNA switch to purify cardiomyocytes, we
further focused on the effect of miR-1-switch and evaluated the
corresponding purified cardiomyocytes. We analyzed the gene
expression levels and electrophysiological state of the miR-1-
switch-sorted cells. qRT-PCR analysis demonstrated that the
sorted cells showed significantly higher expression of cardiac
markers (MYH6, MYH7, MYL2, MYL7, TNNT2, NKX2.5, and
TBX5) and lower expression of non-cardiomyocyte markers
(PECAM1, THY1, and PDGFR-beta) compared with negative
fraction cells and unsorted cells (Figure S3B). In addition, action
potential recordings detected both ventricular-like and atrial-like
waveforms in the purified cardiomyocytes (Figure S3C).
To assess any possible side effects of the reporter mRNA and
miR-1-switch transfection on cardiomyocytes, we analyzed re-
sidual levels of the mRNA and protein in EGFP+ cardiomyocytes
derived from MYH6-EIP4 hiPSCs. After the transfection of BFP
mRNA, the expression level of BFP proteins from modRNA
reached a plateau between 12-24 hr and decreased to near
background levels in 7 days (Figure 3E). We also analyzed resid-
ual EGFP mRNA levels in miR-1-switch-sorted cardiomyocytes
derived from 201B7 cells using qRT-PCR and found that
transfected mRNAs were immediately degraded within 48 hr
(Figure 3F). Next, we investigated whether the transfected
miR-1-switch (miR-208a- and miR-499a-5p-switches) could
deplete the endogenous miR-1 (miR-208a and miR-499a-5p) in
MYH6-EGFP-sorted cardiomyocytes. qRT-PCR analysis re-
vealed that the total amount of endogenous miR-1 (miR-208a
and miR-499a-5p) underwent only minimal changes between
cardiomyocytes before and 24 hr after transfection (Figure 3G)
and between cardiomyocytes with and without transfection of
the corresponding switches (Figures 3G and S3D). In addition,
we investigated whether miR-1-switch transfection affected
global gene expression patterns, including those of miR-1 target
genes. We performed microarray analysis, and the hierarchical
clustering of all genes and miR-1-target genes revealed that
the expression profiles of miR-1-switch-transfected cells were
similar to non-transfected cells at both one day (day 19) and
7 days (day 25) after transfection (Figure 3H). Moreover, qRT-
PCR analysis of GATA4 andHAND2, which are known target car-
diac genes of miR-1, showed that no significant differences were
observed between transfected and non-transfected cells at 24 hrand 72 hr after transfection (Figure S3E). Therefore, miR-1-
switch had no significant side effects and maintained normal
gene expression profiles in cardiomyocytes.
Selective Apoptosis Control and Cardiomyocyte
Purification without Cell Sorting
One of the merits when using miRNA switches is the versatility
of the ORF used in the mRNA sequence. For example, we
could incorporate a desired transgene into the miRNA switches
to control the cell phenotype based on miRNA activity. Thus,
we investigated whether miR-Bim-switch, which regulates
selective cell death, could be employed to concentrate cardio-
myocytes from heterogeneous cell populations without cell
sorting. Both miR-1- and miR-208a-Bim-switches were con-
structed; these switches were designed to induce apoptosis
selectively in cells other than cardiomyocytes (Figure 4A). To
select for the transfected cells, we simultaneously transfected
puromycin resistance mRNA (puror-mRNA), which triggered
the death of non-transfected cells when culturing in the pres-
ence of puromycin (Figure 4A). First, we optimized the concen-
trations of puromycin and puror-mRNA (Figures S4A and S4B)
and then transfected miR-1- or miR-208-switches with puror-
mRNA into hPSC-derived cells. Importantly, miR-1- and miR-
208a-Bim-switches enabled the highly specific purification
of cTNT+ cardiomyocytes without cell sorting (Figure 4B).
Immunohistochemical analysis confirmed that almost all of
the surviving cells expressed cTNT proteins (Figure 4C). The
recovered proportions of 201B7-, 409B2-, and KhES1-derived
cardiomyocytes under 75 ng/ml miR-208a-Bim conditions
were 90.0% ± 7.9%, 90.5% ± 2.5%, and 89.0% ± 4.1%,
respectively (Figure 4D). These recovery yields were higher
than the transfection efficiency (Figure 3E) probably because
of the efficient proliferation of the surviving cardiomyocytes.
Activating cell death by Bim induction may have potentially
harmful side effects on the surviving cardiomyocytes. We
therefore investigated the hierarchical clustering of cell death
pathway-related genes and revealed that the expression
profiles of miR-208a-Bim-switch-transfected cardiomyocytes
were similar to non-transfected cardiomyocytes at one day
(day 19), 3 days (day 21), and 7 days (day 25) after transfection,
indicating negligible harmful side effects of miR-Bim-switch
transfection on the surviving cardiomyocytes (Figure S4C).
Taken together, our miR-Bim-switch system is a highly efficient
and safe purification method for cardiomyocytes without the
need for cell sorting.
Transplantation of Cardiomyocytes Purified by miRNA
Switch
To demonstrate whether this technology is applicable for
cardiomyocyte transplantation therapy, we transplanted miR-
208a-Bim-switch-purified cardiomyocytes into the hearts of
non-obese diabetic/severe combined immunodeficiency inter-
leukin-2 receptor gnull (NOD/Shi-scid Il2rgnull; NOG) mice with
acute myocardial infarction. In this experiment, we used a lucif-
erase reporter-expressing hiPSC line to detect the 1 3 106 car-
diomyocytes that were purified by miR-208a-Bim-switch and
transplanted into the heart. We detected the luciferase signal
for more than 3 months (Figure 5A). Immunostaining demon-
strated that transplanted cells (human nuclei [hN]-positive cells)Cell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc. 703
Figure 3. Purification of hPSC-Derived Cardiomyocytes Using miRNA Switches
(A and B) The average post-purification percentages of cTNT+ cells from 201B7-derived cells (A, n = 3) and from cells derived from another four hPSC lines
(B, n = 3–4) using several purification methods. The error bars represent the SD.
(legend continued on next page)
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Figure 4. Non-Sorting SystemUsingmiRNA
Switches Containing the Bim Sequence
(A) Scheme of cardiomyocyte purification using
miR-Bim-switch and puromycin resistance mRNA
selection.
(B) Average percentage of cTNT+ cells after puri-
fication using miR-1-Bim-switch and miR-208a-
Bim-switch in three hPSC lines. The error bars
represent the SD (n = 3).
(C) Immunostaining for cTNT expression in non-
purified and miR-208a-Bim-switch-purified cells.
The nuclei were stained with Hoechst. Scale bars
represent 100 mm.
(D) Recovery proportion of CMs using miR-Bim-
switch. The recovery rate was calculated by
dividing the cell number of each sample by the
number of non-purified samples. The error bars
represent the SD (n = 3).
See also Figure S4.were robustly engrafted, survived in the heart, and expressed
cTNT (Figure 5B). For functional restoration of the host heart in
cardiac cell therapy, the transplanted cardiomyocytes should
be well integrated with the host myocardium, and previous re-
ports have highlighted the importance of gap junction formation
for functional integration (Caspi et al., 2007; Gepstein et al.,
2010). We thus evaluated the expression of Connexin 43
(Cx43), which is one of major components of gap junctions in
ventricular myocardium. Immunostaining revealed Cx43 expres-
sion between the host heart and transplanted cells (Figures 5C–
5F), suggesting the formation of gap junctions. Importantly, no
tumor formation was observed in the transplanted hearts when
the mice were sacrificed.
To further investigate the tumorigenicity of miRNA switch-
purified cardiomyocytes, 2 3 104 hiPSCs (201B7), 2 3 105
201B7-derived non-purified cells, 2 3 105 miR-1-BFP-switch-
sorted cardiomyocytes, or miR-208a-Bim-switch-purified cardi-
omyocytes were injected into the testes of immunodeficient
(SCID) mice. Approximately 3 months later, we observed tumor
formation in six of the six mice injected with hiPSCs, one
of the eight mice injected with non-purified cells, and zero of(C) Immunohistochemical analysis of cTNT expression in miR-1-, miR-208a-, andmiR-499a-5p-switch-sorted
stained with Hoechst. Scale bars represent 100 mm.
(D) Average percentages of cTNT+ cells after purification by several methods in three hPSC-derived cell lines
represent SD (n = 3).
(E) Flow cytometric analysis of BFP from 12 hr to day 7 after BFP mRNA transfection into day 18 EGFP+ card
error bars represent the SD (n = 3).
(F) Analysis of residual EGFP mRNA levels by qRT-PCR. The day after transfection, total RNA was extracted
samples, and the other miR-1-switch-sorted cells were cultured for another 6 days. Total RNA was sampled o
(n = 3).
(G) Analysis of endogenous miR-1 expression by qRT-PCR. The data are shown as the mean ± SD (n = 3).
(H) Hierarchical clustering of gene expression profiles of hiPSCs, day 18 cardiomyocytes (CMs), day 19 CMs
CMs with or without transfection on day 18. EGFP+ cardiomyocytes derived from MYH6-EIP4 hiPSCs were s
and cultured. miR-1-switch was transfected into the cells on day 18. miR-1 target genes were selected from
n = 3.
See also Figures S2 and S3 and Table S1.
Cell Stem Cell 16, 699–eight mice injected with the miR-1-BFP-
switch-sorted and miR-208a-Bim-puri-
fied cells (Figures 5G and H). Histological
examination showed that the tumorsgenerated by the hiPSCs (six of six) and non-purified cells (one
of eight) contained tissues of the three embryonic germ layers
(Figure S5A). In contrast, the tumor-free transplanted testes of
the non-purified cell group (seven of eight), the miR-1-BFP-
switch-sorted cell group (eight of eight), andmiR-208a-Bim-puri-
fied cell group (eight of eight) were histologically similar to normal
mouse testes (Figure S5B). Taken together, miRNA switch-puri-
fied cardiomyocytes were engrafted and survived in the hearts
and did not form tumors, even when injected into the testes.
Purification of Endothelial Cells, Hepatocytes, and
INSULIN-Producing Cells Derived from hPSCs Using
miRNA Switches
An attractive feature of the miRNA switch is its availability in
many types of cells. Therefore, we investigated whether cell-
type-specific miRNA switches could purify endothelial cells,
hepatocytes and INSULIN-producing cells derived from hPSCs.
For endothelial cells, we selected specific miRNA candidates
from pooled human umbilical vein endothelial cells (HUVECs)
using miRNA microarray analysis and synthesized the top
five miRNA switch candidates with BFP as the reporter againcells and in negative fraction cells. The nuclei were
at the early phase of differentiation. The error bars
iomyocytes derived from MYH6-EIP4 hiPSCs. The
from part of the miR-1-switch-sorted cells as day 1
n each day. The data are shown as the mean ± SD
with or without transfection on day 18, and day 25
orted on day 16 after the initiation of differentiation
miRTarBase (http://mirtarbase.mbc.nctu.edu.tw);
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Figure 5. Transplantation of Purified Cardiomyocytes into Mouse Hearts and Testes
(A) Luciferase imaging by IVIS after the transplantation of miR-208a-Bim-switch-purified cardiomyocytes (n = 3).
(B) Representative immunostaining of heart sections for cTNT and human nuclei (hN) at approximately 3 months after transplantation. The nuclei were stained
with Hoechst. Scale bars represent 500 mm.
(C) Magnification of (B). Scale bars represent 50 mm.
(D) Serial section image of (C). Immunostaining for Cx43 and cardiac Troponin I (cTNI). Scale bars represent 50 mm.
(E and F) Magnification of (C) and (D), respectively. White arrows point to the Cx43 expression between host and transplanted cardiomyocytes.
(G) Tumor formation capacities of 23 104 hiPSCs, 23 105 non-purified cells, 23 105miR-1-BFP-sorted CMs, andmiR-208a-Bim-purified CMs at approximately
3 months after transplantation into the testes.
(H) The graph represents the tumor incidences of each group (hiPSCs, n = 6; non-purified cells, n = 8; miR-1-BFP-sorted CMs, n = 8; miR-208a-Bim-purified CMs,
n = 8).
See also Figure S5.(Figures S6A and S6B). We transfected these miRNA switches
individually with control EGFP mRNA into HUVECs and then
confirmed that miR-126-3p- and miR-126-5p-switches reacted
in the transfected HUVECs (Figure S6B). We next investigated
whether miR-126-3p- and miR-126-5p-switches could isolate
endothelial cells from hPSC-derived differentiated cells, which706 Cell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc.were induced using the same method for cardiomyocyte differ-
entiation and which contained approximately 5%–10% CD31+
cells: CD31 is a marker for endothelial cells. miR-126-3p- and
miR-126-5p-switches allowed highly selective purification of
CD31+ cells from the heterogeneous cell populations of the
four differentiated hPSC lines. In contrast, miR-208a-switch,
which enabled purification of cardiomyocytes, did not enrich
CD31+ cells, indicating high cell specificity for each of themiRNA
switches (Figures 6A and 6B). In addition, a tube formation assay
demonstrated that the cells sorted by miR-126-5p-switch had
angiogenic potential (Figure 6C). For hepatocytes, we selected
specific miRNA candidates from primary hepatocytes using
miRNA microarray analysis and synthesized the top five miRNA
switch candidates with BFP (Figure S6C). miR-122-5p-
switch efficiently purified ALBUMIN+ and HNF4A+ hepatocytes
derived from hiPSCs (Figures 6D and 6E). Immunostaining also
confirmed that most of the cells sorted by miR-122-5p-switch
were ALBUMIN+ hepatocytes (Figure 6F). For INSULIN-produc-
ing cells, we selected several specific miRNA candidates from
previous reports (Francis et al., 2014; Lahmy et al., 2014; Ozcan,
2014) because primary INSULIN-producing cells could not be
obtained and there is no effective method to purify INSULIN-pro-
ducing cells derived from hPSCs using specific surface markers.
Interestingly, we found that miR-375-switch detected and sepa-
rated part of the cells after the induction of INSULIN-producing
cell differentiation using hiPSCs (Figure S6D). We sorted the
detected cells and analyzed the cells by immunostaining; most
of the sorted cells by miR-375-switch were INSULIN+ cells (Fig-
ures 6G, 6H, and S6E). These results indicate that the miRNA
switch approach is applicable to the purification of a variety
of cell types, including cells in which specific surface markers
have not been identified.
Simultaneous Purification of Cardiomyocytes and
Endothelial Cells Using a Tandem miRNA Switch
Finally, we tested whether a single miRNA switch that responds
to twomiRNAs could simultaneously purify both cardiomyocytes
and endothelial cells from a heterogeneous population derived
from hPSCs. We synthesized four types of mRNA that included
a tandem target miRNA sequence that combined miR-208a for
cardiomyocytes with miR-126-3p and miR-126-5p for endothe-
lial cells (Figure 7A). All four tandem miRNA switches purified
cTNT+ cardiomyocytes and CD31+ endothelial cells effectively
and simultaneously, although the BFP intensity in miR-126-
5p+miR-208a-switch-transfected cells was weakly repressed
compared with those cells transfected with the other three
switches (Figures 7B and 7C).
DISCUSSION
In this study, we demonstrated that miRNA switches have great
potential for the detection and purification of living target cells.
Our designed miRNA switches allowed highly accurate and effi-
cient isolation of functional cardiomyocytes derived from hPSCs.
This system depends on only two distinct properties for purifica-
tion: the miRNA switch is transfected into the cells, and specific
miRNAs are used to identify the target cells. The simplicity of
this method enables easy purification of desired cell types by
employing appropriate miRNA switches. In addition, miR-Bim-
switch, which selectively induces apoptosis in non-target cells,
was used to purify cardiomyocytes without cell sorting (Fig-
ure 4B). Future clinical application of hPSC-derived cardiomyo-
cytes requires large-scale purification that is not suitable for cell
sorting. miR-Bim-switch not only provides high purity but also
high yield, achieving an approximately 90% recovery rate forcardiomyocytes (Figure 4D). Thus, a system that controls
apoptosis based on miRNA activity selectively kills non-target
cells and autonomously recovers purified cardiomyocytes from
a heterogeneous cell population.
During the screening of active miRNAs expressed in hPSC-
derived cardiomyocytes, we found that miR-1-, miR-208a-,
and miR-499a-5p-responsive mRNAs purified cardiomyocytes
from five hPSC lines at more than 95% efficiency. The purity of
the cardiomyocytes isolated by these miRNA switches was
higher compared with those purified by previously reported
methods using antibodies for cell surface markers (Dubois
et al., 2011; Elliott et al., 2011; Uosaki et al., 2011). Furthermore,
most of the unselected cardiomyocytes by these miRNA
switches were non-transfected cells (Figure S2D). Thus,
improvements in RNA transduction technology should lead to
better efficiencies by the miRNA switch method outlined here.
Interestingly, miR-208a-switch efficiently purified cardiomyo-
cytes even during the early phase of differentiation, whereas
miR-1-switch modestly enriched these cells, and miR-499a-
5p-switch did not detect these cells, suggesting that the function
of each miRNA switch is specific to the differentiation stage (Fig-
ure 3D). Such knowledge could be exploited further to isolate
cardiomyocytes of varying stages of maturity, which may influ-
ence the efficacy of the subsequent transplantation.
There is a concern that the transfection of synthetic mRNA
might provoke innate antiviral and toxic responses. We therefore
used a modified RNA previously reported to minimize the
immune response (Kormann et al., 2011; Warren et al., 2010;
Zangi et al., 2013) and observed that most of the transfected
mRNAs were degraded within 48 hr after transfection, such
that endogenous miRNA was not depleted, and the miRNA
switch did not significantly influence the global gene expression
pattern or the miRNA-target genes (Figures 3E–3H). Further-
more, we confirmed that isolated cardiomyocytes were suc-
cessfully engrafted and survived after their injection into the
hearts of NOG mice (Figures 5A–5F). These data demonstrate
the clinical potential of synthetic miRNA switches.
To isolate cardiomyocytes, we identified 14 candidate
miRNAs, of which 8 miRNA switches did not react despite the
different expression levels between cardiomyocytes and other
cell types (Figure 2D). Similarly, we identified two miRNAs that
could be used to purify endothelial cells among the five miRNAs
that showed distinct expression patterns in the miRNA array.
There are several possible explanations for the functional differ-
ences betweenmiRNA switches. ThemiRNA array may have de-
tected both active (high translational repression ability) and inac-
tive (no translational repression ability) miRNAs expressed in the
cells. In fact, miRNA sensor and decoy library-based studies
have reported that more than 60% of detected miRNAs do not
show discernible activity (Mullokandov et al., 2012). Another
possibility is that the sequence of the miRNA (and its anti-sense)
and the secondary structure of the miRNA switch may affect the
affinity between the two RNAs. Understanding the responsible
molecular mechanisms would expand the application of de
novo miRNA switches for cell purification. Additionally, active
miRNAs that distinguish target cells could be determined by a
functional screening approach using the miRNA switch library.
In summary, we demonstrated that a miRNA switch system
enables high purification of cardiomyocytes, endothelial cells,Cell Stem Cell 16, 699–711, June 4, 2015 ª2015 Elsevier Inc. 707
(legend on next page)
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Figure 7. Simultaneous Purification of hPSC-Derived Cardiomyocytes and Endothelial Cells Using Tandem miRNA Switches
(A) Scheme of tandem miRNA switches.
(B) Representative flow cytometry plots of tandem miRNA switches expressed in 201B7-derived cells. The solid line represents the repressed BFP signal using
each miRNA switch at day 20. BFP repression-sorted cells were analyzed by staining for CD31 and cTNT.
(C) The average percentages of CD31+ and cTNT+ cells in three hPSC-derived cells after purification by tandemmiRNA switches. The error bars represent the SD
(n = 3).hepatocytes, and INSULIN-producing cells differentiated from
hPSCs without affecting cellular properties. Its versatility and
safety make this technology a promising tool for both basic
and clinical stem cell research.
EXPERIMENTAL PROCEDURES
Plasmid Construction
The multiple cloning site of the pGEM T-easy vector (Promega) was modified
to obtain a pAM empty vector via PCR-based site-directed mutagenesis using
the primer set FwdMCS and RevMCS. Next, the protein-coding region of
EGFP (Clontech) or tagBFP (Evrogen) was amplified via PCR using the primerFigure 6. Purification of Endothelial Cells, Hepatocytes, and INSULIN-
(A) Representative flow cytometry plots of miR-126-3p-, miR-126-5p-, and miR-
repressed BFP signal for each miRNA switch. After sorting the cells in the repress
(B) The average percentages of CD31+ cells after purification by miR-126-3p-, m
represent the SD (n = 3).
(C) Tube formation assay of HUVECs and miR-126-5p-switch-purified endothelia
(D) Left: representative flow cytometry plots of miR-122-5p-switch-transfected ce
the repressed BFP signal and negative fraction, the cells were analyzed by stain
(E) The average percentages of ALBUMIN+ and HNF4A+ cells in 201B6-derived
(n = 3).
(F) Immunohistochemical analysis of ALBUMIN expression in miR-122-5p-switc
stained with Hoechst. Scale bars represent 100 mm.
(G) Immunohistochemical analysis of INSULIN expression in miR-375-switch-sor
and non-sorted cells. The nuclei were stained with Hoechst. Scale bars represen
(H) The average percentage of INSULIN+ cells after purification by miR-375-swit
See also Figure S6.sets CFwdEGFP and CRevEGFP or CFwdtagBFP and CRevtagBFP. The PCR
products were digestedwith NcoI and BglII and inserted into the NcoI and BglII
sites of pAM to obtain pAM-EGFP and pAM-tagBFP. To generate 50 UTRs con-
taining the miR-21-5p or miR-17-5p target site, pairs of oligo-DNAs,
5Tmi21_Afwd and 5Tmi21_Arev or 5Tmi17_5_Afwd and 5Tmi17_5_Arev,
were annealed and inserted into the BamHI and AgeI sites of 18nt-2xFr15-
ECFP (Endo et al., 2013). Then, the 50 UTR was amplified using the primer
set T7FwdA and Rev50 UTR. The primer sequences and the PCR reaction con-
ditions are provided in Tables S2 and S3, respectively.
Preparation of Template DNA for IVT
50 and 30 UTRs without miRNA target sequences (control UTRs) and the pro-
tein-coding regions of reporter mRNAs were prepared by PCR with properProducing Cells Derived from hPSCs Using miRNA Switches
208a-switches in 201B7-derived cells at day 20. The solid line represents the
ed BFP signal and negative fraction, the cells were analyzed by CD31 staining.
iR-126-5p-, and miR-208a-switches in four hPSC-derived cells. The error bars
l cells derived from hPSCs. Scale bars represent 100 mm.
lls derived from a hiPSC clone (201B6) at day 17. Right: after sorting the cells in
ing for ALBUMIN and HNF4A.
cells after purification by miR-122-5p-switch. The error bars represent the SD
h-sorted cells, negative fraction cells and non-sorted cells. The nuclei were
ted cells derived from a hiPSC clone (585A1) at day 18, negative fraction cells,
t 100 mm (top) and 50 mm (bottom).
ch. The error bars represent the SD (n = 3).
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primer sets from plasmids and synthesized oligo-DNAs, respectively. The PCR
fragments of the 50 UTR (10 pmol), a coding region (50 ng), and the 30 UTR (10
pmol) were fused to generate DNA templates for IVT via a further PCR reaction
with the primer set T7FwdG3C (or T7FwdA) and Rev120A. Oligo-DNAs and the
T7FwdB primer were also used in the fusion PCR instead of the PCR products
of the UTRs or T7Fwd5UTR primer, respectively. The primer sequences and
the PCR reaction conditions are provided in Tables S2 and S3, respectively.
The PCR products were purified using a MinElute PCR purification kit
(QIAGEN) according to the manufacturer’s instructions. Before purification,
the PCR products amplified from plasmids were subjected to digestion with
the Dpn I restriction enzyme (Toyobo) for 30 min at 37C.
mRNA Synthesis and Purification
miRNA-responsive mRNAs were generated using a MegaScript T7 kit
(Ambion) and a modified protocol (Warren et al., 2010). In the reaction,
pseudouridine-50-triphosphate and 5-methylcytidine-50-triphosphate (TriLink
BioTechnologies) were used instead of uridine triphosphate and cytosine
triphosphate, respectively. Guanosine-50-triphosphate was 5-fold diluted
with Anti-Reverse Cap Analog (New England Biolabs) before the IVT reaction.
Reaction mixtures were incubated at 37C for 4 hr, mixed with TURBO DNase
(Ambion), and further incubated at 37C for 30 min. The resulting mRNAs were
purified using a FavorPrep Blood/Cultured Cells total RNA extraction column
(Favorgen Biotech), incubated with Antarctic Phosphatase (New England Bio-
labs) at 37C for 30 min, and then purified again using an RNeasy MiniElute
Cleanup Kit (QIAGEN).
miRNA and mRNA Microarray Analysis
miRNA and mRNA expression profiling was performed using the Agilent
Technologies Human miRNA Microarray Release 19.0 and the SurePrint G3
Human GE Microarray according to the manufacturers’ protocols, respec-
tively. The data were analyzed using GeneSpring GX 12.6 software (Agilent
Technologies).
Reverse Transcription and qPCR
For the detection of mRNA transcripts, purified RNA was reverse transcribed
using a ReverTra Ace-a-kit (Toyobo) with the oligo(dT)20 primer. For miRNA,
purified total RNA was reverse transcribed using miR-1 and RNU6B Taqman
probes (Applied Biosystems). Quantitative PCR (qPCR) was performed with
the Taqman probes, and the samples were analyzed using a StepOne Plus
Real-Time PCR System (Applied Biosystems). The Taqman probes are shown
in Table S4.
Tube Formation Assay
HUVEC and miR-126-5p-switch-sorted cells were seeded in a Matrigel-
coated 24-well plate at 2 3 105 cells/well in EGM-2 BulletKit medium. The
next day, images of the samples were acquired using a Biorevo BZ-9000
microscope.
Statistical Analysis
The data are presented as the means and SDs of the experiments. Student’s
t test was used for the statistical analysis.
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